Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. - Wikidata - wikimedia - TriplyDB

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

http://www.wikidata.org/entity/Q36222669

about

Androgens for the anaemia of chronic kidney disease in adults Erythropoietin or darbepoetin for patients with cancer Drug therapy for the management of cancer-related fatigue Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data Drug therapy for the management of cancer related fatigue Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data Androgens for the anaemia of chronic kidney disease in adults Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response?AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival.Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression.Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE.Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors.Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.Assessing the quality of prescribing and monitoring erythropoiesis-stimulating agents in the nursing home setting.Erythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis.Patterns of erythropoiesis-stimulating agent use for chemotherapy-induced anemia in lung cancer: results of a retrospective Hungarian real-life clinical data analysis.Erythropoiesis-stimulating agent use after changes in medicare reimbursement policies.Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression.Medicare coverage for erythropoiesis-stimulating agents: the perfect storm Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance.The ESA APPRISE Oncology Program: A History of REMS Requirements, a Review of the Data, And an Approach to Compliance in the Hospital.Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial.AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014.Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools.The influence of Erythropoietin on platelet activation, thrombin generation and FVII/active FVII in patients with AMI.Erythropoietin suppresses the activation of pro-apoptotic genes in head and neck squamous cell carcinoma xenografts exposed to surgical trauma.Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines.Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Cancer-related fatigue: clinical practice versus practice guidelines.Post-diagnosis hemoglobin change associates with overall survival of multiple malignancies - results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers.An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost.Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer.

P2860

Q24193138-0107333E-B4E8-4672-ABF5-587F0980F06F Q24202335-16041FD4-92CB-4173-882B-36779A5F2ED5 Q24234267-8966763D-4B98-4C53-9467-9FFB297082DF Q24240202-A8481107-74BC-404F-867B-B7544539B8CA Q24242050-BB900EBB-13D1-46A2-A53C-B5BCB50B9824 Q24242864-6DE04D4F-94A7-4A55-823C-253762B6D228 Q24242990-167B3F0D-97BE-4037-8738-2B4D9DEDEF11 Q24651385-23C74B51-3F89-43F0-84C5-C0AD16288A88 Q27343148-FCF0CEF6-158D-483A-B2E5-4EBA2C4BAE6C Q30453014-599C28A2-2734-4C33-8E8F-60F1CA41B431 Q30803363-DA20A674-1651-4DD4-ABDB-69D203692D86 Q33243661-74913870-E241-4460-8025-92BB807EA7C5 Q33288270-6459F2B0-DEDD-4487-8B8A-FD50E0FBE7AA Q33326648-4740D2E5-2165-4C0A-B5E8-08675F880A79 Q33499897-01CC05A2-8ABF-4227-8CCB-04F4B20A364E Q33630871-8EFDE163-257E-40AA-8395-365E799E8F7A Q33654147-EA21D438-1A9A-42E9-87EA-15316E44F347 Q33659628-BF57962F-426D-4C94-AF0B-80CD2B76DBE5 Q33727356-EF2D6992-4860-446D-9DDF-3C7779579131 Q33757650-746701EA-0789-489E-9FB0-87A2CA2E3EBE Q33827405-D1694DAC-9F30-451C-987A-31627E63E637 Q33867969-2B82AE91-5996-4D76-A4F5-B9DAB2BB49E4 Q33890476-2EE9F554-00A2-4DE3-B995-63B06DE9804C Q33920934-0B0F1216-451F-4511-8608-F92D3C605908 Q33932540-ADD49134-4E49-4244-9049-CF03BB11B987 Q34006181-FCDCB714-AC7F-4902-8FCA-ABCB4E840441 Q34022950-EC9D3562-3DFF-462D-BA55-62BE19B72279 Q34024987-E7F27D0B-7FDE-4D87-B3D0-73C8AAA395A9 Q34042768-B8982CA3-5BB7-4D70-BEA8-E5810A0BD97D Q34068226-57B87EDE-CFA3-4140-A6D5-132A82AE282A Q34095827-8FBEC5DC-272D-4A9B-8C6F-B0F8A1196045 Q34193545-B9CC66D0-FF5A-4625-A678-83E69CF3A324 Q34217187-C460A69C-504E-435E-AF07-F1DC004E28D4 Q34399172-1B337CFE-13EC-4E83-9FF9-C1BAAAB3CA16 Q34624263-FCE83B1A-1996-43F1-9AF6-8FF90D5A4AC2 Q34635638-9A7553AF-3B71-416B-9F22-49D244971534 Q34700299-010BB0BF-5CAF-486F-8D6E-A38BF21F0049 Q34810071-95F26212-AC43-4B85-86FA-4EA4AA6ED0B0 Q34896347-E2E9D47A-BC06-450F-9175-CB8D92CD8A36 Q34961213-48FA51A3-5A61-41EE-90E4-6C1AA0BCCDE3

P2860

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

http://www.wikidata.org/entity/Q36222669

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Maintaining normal hemoglobin ...... hemotherapy: a survival study.

@ast

Maintaining normal hemoglobin ...... hemotherapy: a survival study.

@en

type

label

Maintaining normal hemoglobin ...... hemotherapy: a survival study.

@ast

Maintaining normal hemoglobin ...... hemotherapy: a survival study.

@en

prefLabel

Maintaining normal hemoglobin ...... hemotherapy: a survival study.

@ast

Maintaining normal hemoglobin ...... hemotherapy: a survival study.

@en

P1433

Q36222669-D4D1A426-16CA-4337-B025-0F284705F3FF

P1476

Q36222669-4E5EA7A4-76C6-406D-9DC8-9F8FD48242B7

P2093

Q36222669-22EF2BE1-53D8-4CBF-A907-3565DB344680

Q36222669-2E7E82A6-6BDC-48DF-9B7D-1671FCD8945A

Q36222669-5FC48106-A3F6-49E3-AB0A-53402D580B93

Q36222669-60C2C66E-998D-4F84-9C45-32D2C6A52F46

Q36222669-7283FDAE-2C1E-4A1B-9358-8919EFD105F5

Q36222669-75782733-E46A-4DCB-88C9-AFB68674766D

Q36222669-7D592F77-EDE7-426E-88AD-613E6D57D8F1

Q36222669-A2634326-B09E-4EA6-B2F3-34F59EDEF707

Q36222669-BEB0C87A-2B2D-4EE7-8073-DA16A5F62628

Q36222669-D7234A60-9CE8-4CEE-83C4-150AF7B58AAC

P304

Q36222669-73FEA5B0-9187-42E3-938D-CD62ED1104E6

P31

Q36222669-EDE0BA2E-A426-4C35-9346-7A5A1B1E78A6

P356

Q36222669-EC18A191-23B4-479A-93B4-A230EDA38C28

P407

Q36222669-B5A44E67-3FCF-4C40-8E25-6DCEC05F2248

P433

Q36222669-F3149C67-59A5-4E3D-AAF9-E17C16447CAF

P478

Q36222669-54863F39-E93F-4E92-8AE0-D7798B882FCF

P50

Q36222669-4B6A4427-B1F2-493D-8DFD-2865A0886621

Q36222669-ACA62901-7E84-4855-8936-95800BA438F8

P577

Q36222669-C45F10DA-187B-479F-AB0D-5C8369A330CD

P5875

Q36222669-1757DB70-F224-4EF2-B8F9-DDA6ED975A98

P698

Q36222669-60A55273-CE21-4BDD-85CD-C2D703CE6BA0

P921

Q36222669-59E437D0-8762-463E-8D05-9E02E867B8D8

P356

JCO.2005.06.150

P1433

Journal of Clinical Oncology

P1476

Maintaining normal hemoglobin ...... hemotherapy: a survival study.

@en

P2093

Antoly Makhson

http://www.w3.org/2001/XMLSchema#string

Anton Roth

http://www.w3.org/2001/XMLSchema#string

Brian Leyland-Jones

http://www.w3.org/2001/XMLSchema#string

David Dodwell

http://www.w3.org/2001/XMLSchema#string

Edouard Voznyi

http://www.w3.org/2001/XMLSchema#string

Els Vercammen

http://www.w3.org/2001/XMLSchema#string

George Manikhas

http://www.w3.org/2001/XMLSchema#string

Konstantinas Valuckas

http://www.w3.org/2001/XMLSchema#string

Marek Pawlicki

http://www.w3.org/2001/XMLSchema#string

Mikhail Biakhov

http://www.w3.org/2001/XMLSchema#string

P304

5960-5972

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.06.150

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Tadeusz Pieńkowski

P577

2005-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7672237

http://www.w3.org/2001/XMLSchema#string

P698

16087945

http://www.w3.org/2001/XMLSchema#string

P921